What’s New in the Management of COVID-19
Incorporating New Data and Updated Guidelines Into Daily Practice
Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir.
Akinosoglou K, Schinas G, Gogos C. Viruses. 2022;14(11):2540.
Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.
Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.
Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19).
Boucau J, Uddin R, Marino C, et al. Clin Infect Dis. 2023;76(3)e526-e529.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial.
Butler C, Hobbs R, Gbinigie O, et al. Lancet. 2022. [Epub ahead of print]
Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with Covid-19.
Ganatra S, Dani SS, Ahmad J, et al. Clin Infect Dis. 2022. [Epub ahead of print]
Early remdesivir to prevent progression to severe Covid-19 in outpatients.
Gottlieb RL, Vaca CE, Paredes R, et al. N Engl J Med. 2022;386(4):305-315.
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.
At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.
Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.
Imai M, Ito M, Kiso M, et al. N Engl J Med. 2023;388(1):89-91.
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review.
Notarte KI, Catahay JA, Velasco JV, et al. EClinicalMedicine. 2022;53:101624.
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q, Iketani S, Li Z, et al. Cell. 2023;186(2)279-286.e8.
Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir.
Wong GL, Yip TC, Lai MS, et al. JAMA Netw Open. 2022;5(12):e2245086.
Impact of metabolic syndrome on severity of COVID-19 illness.
Wu S, Zhou K, Misra-Hebert A, et al. Metab Syndr Relat Disord. 2022;20(4):191-198.
Nirmatrelvir and the risk of post-acute sequelae of COVID-19.
Xie Y, Choi T, Al-Aly Z. medRxiv. 2022:2022.2011.2003.22281783.
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
Yue C, Song W, Wang L, et al. Lancet Infect Dis. 2023;23(3):278-280.
Patient Poster
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH).
Clinician Resources
Test to Treat.
Administration for Strategic Preparedness & Response (ASPR).
Isolation and precautions for people with COVID-19.
Centers for Disease Control and Prevention (CDC).
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States.
CDC.
Trends in number of COVID-19 cases and deaths in the US reported to the CDC, by state/territory.
CDC.
Federal response to COVID-19: therapeutics clinical implementation guide.
Department of Health and Human Services (DHHS).
Fact sheet for healthcare providers: emergency use authorization for Lagevrio™ (molnupiravir).
US Food and Drug Administration (FDA).
Fact sheet for healthcare providers: emergency use authorization for PaxlovidTM.
FDA.
Highlights of prescribing information: Veklury® (remdesivir).
FDA.
What’s New in the Management of COVID-19
Incorporating New Data and Updated Guidelines Into Daily Practice
| Faculty: | Leigh Lewis Speicher, MD, MPH |
| Release: | 03/24/2023 |
| Expiration: | 03/24/2024 |
What Pharmacists Need to Know About Treating COVID-19
Incorporating New Data and Guidelines Into Practice
| Faculty: | Maggie Zhao, PharmD, BCCCP |
| Release: | 03/31/2023 |
| Expiration: | 03/31/2024 |
